Sk Biopharmaceuticals Co Ltd (326030)
Korea Stock Exchange · Korea · prices in KRW · close of 19 Oct 2026
Key indicators
| Last close | KRW 76,200.00 |
|---|---|
| 52-week range | 67,800.00 – 144,100.00 |
| Return, 1 month / 3 months | −3.7% / +2.1% |
| Return, 1 year / 3 years | −24.9% / −7.0% |
| Trend | Below its 200-day average |
| RSI (14) | 50 |
| Volatility (1 year) | 46.5% |
| Worst drawdown (1 year) | -50.7% |
| Average daily value traded | 10,410.85M KRW |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
SK Biopharmaceuticals is a pharmaceutical company based in South Korea that researches and develops medicines for disorders of the central nervous system. Its main product is an epilepsy treatment that it develops and supplies to patients and healthcare providers in markets including the United States and Europe. The company also works on other neurological and oncology candidates through its own research and partnerships, and it earns revenue from product sales and licensing arrangements with pharmaceutical partners.
The shares are listed on the Korea Stock Exchange in Korea under the code 326030, and the price on this page is in South Korean won (KRW). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Sk Biopharmaceuticals Co Ltd (326030) trades on the Korea Stock Exchange in Korea. It last closed at KRW 76,200.00 on 19 October 2026.
Its price-based Market X-Ray is 45 out of 100 (a weak price profile), ranking 578 of 934 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 24.9% and over the last three months it rose 2.1%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Korea Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 27 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -20.3% | ||
| From 52-week high | -45.8% | ||
| Momentum | 39 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | 2.1% | ||
| 6-month return | -22.6% | ||
| 12-month return, skipping the last month | -22.0% | ||
| Stability (higher is calmer) | 46 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 46.5% | ||
| Worst drawdown, 1 year (smaller is calmer) | -50.7% | ||
| Liquidity | 82 · Strong | Trades actively. | |
| Average daily value traded | 10,410.85M KRW | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
- Liquidity: Trades actively.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
- Stability (higher is calmer): Volatile, with deep drawdowns.
Returns
| 1 week | +7.3% |
|---|---|
| 1 month | −3.7% |
| 3 months | +2.1% |
| 6 months | −22.6% |
| 1 year | −24.9% |
| 3 years | −7.0% |
| 5 years | – |
Signals
| 50-day / 200-day average | 81,188.00 / 95,666.50 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 2,922.33 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Korea Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.